<DOC>
	<DOC>NCT02806453</DOC>
	<brief_summary>A randomized controlled cross-over trial in full-term infants affected by symptoms suggestive of GER, evaluated through a validated questionnaire (Infant Gastroesophageal Reflux Questionnaire Revised). The parents of all of the enrolled infants will be reassured on the benign nature of the condition and will advise to apply lifestyle changes for one week. Than, the patients will be randomized into one of the two sequence treatment groups. (group A: Mg alginate/thickened formula; group B: thickened formula/Mg alginate) for two weeks. Evaluation of symptom scores will be performed at day 0, day 7, day 21 and day 35.</brief_summary>
	<brief_title>Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants.</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Alginic acid</mesh_term>
	<criteria>fullterm ages 3 to 12 months, affected by symptoms suggestive of GER. infant regurgitation defined according to the Rome IV criteria informed consent Evidence of chronic diseases, hepatic, renal, or cardiac diseases, metabolic or central nervous system diseases, or use of acid suppressor treatment (H2receptor antagonists or proton pump inhibitors [PPIs]), thickened formula, or a history of prematurity or atopy</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>